Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An Fen Ma Mei is a fixed-dose combination pharmaceutical product developed and manufactured by Zhejiang Kangde Pharmaceutical, specifically formulated as a dry suspension for pediatric use. It is indicated for the relief of symptoms associated with the common cold and influenza in children, including fever, headache, limb pain, sneezing, runny nose, nasal congestion, and cough. The formulation combines four active ingredients: acetaminophen (an antipyretic and analgesic), pseudoephedrine hydrochloride (a nasal decongestant), dextromethorphan hydrobromide (a cough suppressant), and chlorpheniramine maleate (an antihistamine). By targeting multiple pathways—including prostaglandin synthesis, adrenergic receptors, histamine receptors, and the medullary cough center—it provides comprehensive symptomatic relief for upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + chlorpheniramine + dextromethorphan + pseudoephedrine.